Sunil Shah is a Board Observer at Metrion Biosciences and the CEO of the o2h Group which has developed an engine for seeding a pipeline of early stage life science assets through research collaborations, in-licensing, spin-outs & investments.

In 2019, Sunil won the UKBAA Angel Investor of the Year Award as well as the OBN Special Recognition Award for his contribution to the life sciences industry in the UK.

Sunil is a Board Director of Cambridge Angels and also is a member of the Advisory Panel of Cancer Research UK (CRUK). He is also a non-executive director in the Board of Bioindustry Association Ltd. (BIA). He is either Chairman, Director, Board Observer or investor of: Phoremost, Exonate, Opal Oncology, Five Alarm Bio, Somaserve, DeepMatter, Oppilotech, Sentinel, Small Pharma, Arecor, Metrion, Talisman, Stemnovate, Acacia, Privitar and Oxford Drug Design. Sunil has a degree in Biochemistry and an MBA from Cambridge University.